GENETIC ANALYSIS NK -60 (8V8) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GENETIC ANALYSIS NK -60 (8V8) has a cash flow conversion efficiency ratio of 0.297x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€8.04 Million ≈ $9.40 Million USD) by net assets (€27.08 Million ≈ $31.66 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
GENETIC ANALYSIS NK -60 - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how GENETIC ANALYSIS NK -60's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read GENETIC ANALYSIS NK -60 balance sheet liabilities for a breakdown of total debt and financial obligations.
GENETIC ANALYSIS NK -60 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GENETIC ANALYSIS NK -60 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CENTURION FIN.A-C ZY -10
F:6F4
|
N/A |
|
MW Trade S.A.
WAR:MWT
|
-0.064x |
|
World Copper Ltd
V:WCU
|
-2.793x |
|
Vivakor Inc
NASDAQ:VIVK
|
-0.540x |
|
Atomic Minerals Corp
V:ATOM
|
-0.496x |
|
Maison Solutions Inc
NASDAQ:MSS
|
0.205x |
|
SKONEC Entertainment Co. Ltd.
KQ:276040
|
-0.163x |
|
Diablo Resources Ltd
AU:DBO
|
-0.161x |
Annual Cash Flow Conversion Efficiency for GENETIC ANALYSIS NK -60 (2021–2025)
The table below shows the annual cash flow conversion efficiency of GENETIC ANALYSIS NK -60 from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see market value of GENETIC ANALYSIS NK -60.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €27.08 Million ≈ $31.66 Million |
€2.40 Million ≈ $2.81 Million |
0.089x | +117.16% |
| 2024-12-31 | €22.49 Million ≈ $26.30 Million |
€-11.62 Million ≈ $-13.59 Million |
-0.517x | +4.04% |
| 2023-12-31 | €32.00 Million ≈ $37.41 Million |
€-17.23 Million ≈ $-20.15 Million |
-0.539x | -22.17% |
| 2022-12-31 | €44.14 Million ≈ $51.60 Million |
€-19.46 Million ≈ $-22.75 Million |
-0.441x | -15.07% |
| 2021-12-31 | €72.09 Million ≈ $84.28 Million |
€-27.62 Million ≈ $-32.29 Million |
-0.383x | -- |
About GENETIC ANALYSIS NK -60
Genetic Analysis AS, a science-based diagnostic company, develops diagnostic solutions for human microbiome market in the United States, Europe, and internationally. It offers GA-map, a platform for the analysis of the human gut microbiota; GA-map Dysbiosis Test that detects and characterizes dysbiosis; and GA-map Analyzer, a cloud-based software solution. The company also provides GA-map Discove… Read more